Medical Cannabis Registry and Pharmacology

Completed

Conditions studied: Autism, ASD

In brief

The overall goals of this research is to describe the 1) natural history of current use and disposition of medical cannabis products including Cannabidiol (CBD) products, being administered to children as standard of care for the treatment of Autism Spectrum Disorder (ASD), 2) understand the pharmacokinetic and pharmacodynamics of medical cannabis products and 3) provide educational feedback on what is learned to families and care providers to provide evidenced based dosing guidance for these products to the pediatric community.

Key facts

Study ID

NCT03699527

Run by

Children's Hospital of Philadelphia

People needed

119

Starts

2018-07-15

Expected to finish

2020-01-15

Last updated by the study team

2020-01-27

Who can join

Age: any, up to 21. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Individuals who consume cannabis products in a state which has legalized medical cannabis for the treatment of ASD related symptoms
• Individuals who have a diagnosis of autism spectrum disorder

You may not qualify if…

• Consumption of cannabis products that are not obtained legally
• Non English speaking individuals
• Greater than 21 years of age for entry into Part 2 of the study

Where it is running

• Children's Hospital of Philadelphia — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.